Trinity Biotech - ADR Peer Comparison
$9.68
$-0.07
(-0.72%)
As on 28-Aug-2026 16:04EDT
Market cap
$9 Mln
Revenue (TTM)
$54 Mln
P/E Ratio
--
P/B Ratio
5.7
Div. Yield
0 %
Edit
| Trinity Biotech - ADR | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
9 | 12,753 | 12,153 | 10,906 | 10,222 |
Revenue ($ Mln) |
44 | 1,505 | 6,164 | 613 | 785 |
Net Profit ($ Mln) |
-37.38 | 160.59 | 625.00 | -188.05 | 41.54 |
Net Margin (%) |
-68.49 | 10.67 | 5.41 | -30.68 | 5.29 |
RoE (%) |
69.76 | 10.86 | 11.84 | -28.10 | 1.97 |
Price to Earnings |
-- | 79.35 | 19.89 | -- | 251.57 |
Price-To-Book |
5.75 | 8.41 | 2.37 | 16.38 | 4.84 |
Income Statement ($ Mln)
| Trinity Biotech - ADR | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
43.79 | 1,403.67 | 6,164.00 | 507.44 | 738.26 |
|
Cost of Revenue
|
26.90 | 461.23 | 1,957.00 | 114.23 | 390.63 |
|
Gross Profit
|
16.89 | 942.44 | 4,207.00 | 393.22 | 347.62 |
|
Operating Expenses
|
28.30 | 753.19 | 3,413.00 | 479.95 | 288.05 |
|
Operating Profit (EBIT)
|
-11.42 | 189.25 | 794.00 | -86.73 | 59.58 |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
-37.18 | 205.13 | 779.00 | -193.04 | 62.38 |
|
Provision for Tax
|
0.20 | 27.44 | 154.00 | -5.35 | 13.49 |
|
Profit after Tax (Net Income)
|
-37.38 | 177.69 | 625.00 | -187.69 | 48.89 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | 177.69 | 625.00 | -- | -- |
Liabilities ($ Mln)
| Trinity Biotech - ADR | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-71.98 | 1,427.60 | 5,289.00 | 656.16 | 2,106.13 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
35.94 | 215.78 | 3,573.00 | 136.06 | 707.74 |
|
Current Liabilities
|
141.21 | 183.13 | 1,595.00 | 101.28 | 135.83 |
|
Total Liabilities
|
105.17 | 1,826.52 | 10,457.00 | 893.49 | 2,949.70 |
Assets ($ Mln)
| Trinity Biotech - ADR | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
69.26 | 609.84 | 6,354.00 | 418.50 | 1,812.31 |
|
Current Assets
|
35.90 | 1,216.68 | 4,103.00 | 474.98 | 1,137.39 |
|
Total Assets
|
105.17 | 1,826.52 | 10,457.00 | 893.49 | 2,949.70 |
|
Total Debt*
|
137.98 | 219.70 | 3,327.00 | 139.64 | 689.95 |
|
Net Current Assets
|
-105.31 | 1,033.55 | 2,508.00 | 373.71 | 1,001.56 |
Cashflow ($ Mln)
| Trinity Biotech - ADR | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-5.93 | 238.66 | 1,285.00 | -46.34 | 117.42 |
|
Cash Flow from Investing Activities
|
-6.22 | -404.59 | -406.00 | -77.61 | -298.47 |
|
Cash from Financing Activities
|
12.05 | 26.53 | -955.00 | 11.89 | -15.21 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Trinity Biotech - ADR | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-56.81 | 11.76 | 7.27 | -22.53 | 1.79 |
|
ROE (%)
|
69.76 | 13.78 | 11.84 | -26.38 | 2.40 |
|
ROA (%)
|
-35.86 | 10.58 | 6.01 | -20.09 | 1.69 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-85.36 | 12.66 | 10.14 | -36.99 | 6.62 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Trinity Biotech - ADR | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-0.29 | 0.17 | 0.06 | 0.32 | 0.16 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-17.58 | 1,168.11 | 51.70 | -28.23 | 291.64 |
|
EPS Growth (%)
|
0.11 | 11.64 | 0.53 | -0.24 | 2.90 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Trinity Biotech - ADR | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-0.01 | 68.93 | 22.91 | -34.59 | 189.42 |
|
Price / Book Value
|
-0.01 | 8.58 | 2.71 | 9.90 | 4.40 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-6.24 | 53.25 | 12.79 | -43.50 | 55.90 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Trinity Biotech - ADR | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-1.92 | 0.15 | 0.63 | 0.21 | 0.33 |
|
Short term debt to equity ratio
|
-1.54 | 0.01 | 0.03 | -- | 0.01 |
|
Current Ratio
|
0.25 | 6.64 | 2.57 | 4.69 | 8.37 |
|
Quick Ratio
|
0.12 | 4.29 | 1.25 | 4.06 | 7.12 |
|
Interest Coverage
|
-1.83 | 157.46 | 6.21 | -40.65 | 3.69 |
Operating Efficiency Ratios
| Trinity Biotech - ADR | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
23.48 | 13.54 | 23.18 | 21.40 | 21.48 |
|
Asset Turnover
|
0.42 | 0.84 | 0.59 | 0.54 | 0.26 |
|
Receivable days
|
103.80 | 46.54 | 78.10 | 60.95 | 72.41 |
|
Inventory Days
|
259.37 | 331.92 | 420.31 | 193.84 | 146.53 |
|
Payable days
|
124.32 | 26.16 | 209.22 | 60.19 | 29.05 |
|
Cash Conversion Cycle
|
238.85 | 352.30 | 289.19 | 194.60 | 189.88 |
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
